Skip to main content

Advertisement

SpringerLink
Log in

The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

The datasets that were utilized or examined during the current research can be obtained from the corresponding author upon a reasonable request.

References

  1. Tasian SK, Loh ML, Hunger SP (2017) Philadelphia chromosome–like acute lymphoblastic leukemia. Blood 130:2064–2072

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Luca DC (2021) Update on lymphoblastic leukemia/lymphoma. Clin Lab Med 41:405–416

    Article  PubMed  Google Scholar 

  3. Tasian SK, Teachey DT, Li Y, Shen F, Harvey RC, Chen I-M, Ryan T, Vincent TL, Willman CL, Perl AE (2017) Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 129:177–187

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Kucine N, Marubayashi S, Bhagwat N, Papalexi E, Koppikar P, Sanchez Martin M, Dong L, Tallman MS, Paietta E, Wang K (2015) Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood 126:2479–2483

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kołodrubiec J, Kozłowska M, Irga-Jaworska N, Sędek Ł, Pastorczak A, Trelińska J, Młynarski W (2022) Efficacy of ruxolitinib in acute lymphoblastic leukemia: a systematic review. Leuk Res 121:106925

  6. Ofran Y, Izraeli S (2017) BCR-ABL (Ph)-like acute leukemia—pathogenesis, diagnosis and therapeutic options. Blood Rev 31:11–16

    Article  CAS  PubMed  Google Scholar 

  7. Nikolaev SI, Garieri M, Santoni F, Falconnet E, Ribaux P, Guipponi M, Murray A, Groet J, Giarin E, Basso G (2014) Frequent cases of RAS-mutated down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nat Commun 5:4654

    Article  CAS  PubMed  Google Scholar 

  8. Suryani S, Bracken LS, Harvey RC, Sia KC, Carol H, Chen I-M, Evans K, Dietrich PA, Roberts KG, Kurmasheva RT (2015) Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia. Mol Cancer Ther 14:364–374

    Article  CAS  PubMed  Google Scholar 

  9. Zhang Q, Shi C, Han L, Jain N, Roberts KG, Ma H, Cai T, Cavazos A, Tabe Y, Jacamo RO (2018) Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia. Oncotarget 9:8027

    Article  PubMed  PubMed Central  Google Scholar 

  10. Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, Chen X, Ahern CH, Weigel BJ, Blaney SM (2015) A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a children's oncology group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer 62:1717–1724

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S (2015) A phase I/II study of the Janus kinase (JAK) 1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15:171–176

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Marmara Faculty of Medicine, Marmara University, Istanbul, Turkey

    Ozlem Candan, Derya Demirtas, Ahmet Mert Yanik, Isik Atagunduz & Tayfur Toptas

  2. Tissue Typing Laboratory, Marmara Universitesi Pendik Eg ve Ar Hastanesi, Muhsin Yazicioglu cd, No. 10, 34899 Pendik, Istanbul, Turkey

    Ozlem Candan

Authors
  1. Ozlem Candan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Derya Demirtas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmet Mert Yanik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Isik Atagunduz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tayfur Toptas
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to writing, drafting, and editing of the manuscript. Additionally, all authors participated in the final revisions of the manuscript and deserve authorship.

Corresponding author

Correspondence to Ozlem Candan.

Ethics declarations

Ethical approval

This letter does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

The authors declare that they have acquired consent forms from both the patient and their immediate family members. Within these forms, the patient has provided consent for the publication of their medical examinations and other clinical information in the journal. The patient acknowledges that their name and initials will not be disclosed, and measures will be taken to safeguard their identity. However, it should be noted that complete anonymity cannot be guaranteed.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Candan, O., Demirtas, D., Yanik, A.M. et al. The role of ruxolitinib treatment in JAK-mutated Ph-like acute lymphoblastic leukemia. Ann Hematol 102, 3647–3648 (2023). https://doi.org/10.1007/s00277-023-05456-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05456-3

Search

Navigation